Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance

Linnell B Randall^{1

2}, Enrico Georgi³, Gelimer H Genzel³, Herbert P Schweizer^{1

2}

Affiliations

¹ Department of Molecular Genetics & Microbiology, Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA.
² Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
³ Bundeswehr Institute of Microbiology, Munich, Germany.

Linnell B Randall et al. J Antimicrob Chemother. 2017.

. 2017 Apr 1;72(4):1258-1260.

doi: 10.1093/jac/dkw529.

Linnell B Randall^{1

2}, Enrico Georgi³, Gelimer H Genzel³, Herbert P Schweizer^{1

2}

¹ Department of Molecular Genetics & Microbiology, Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA.
² Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
³ Bundeswehr Institute of Microbiology, Munich, Germany.

No abstract available

References

1. Wiersinga WJ, Currie BJ, Peacock SJ.. Melioidosis. N Engl J Med 2012; 367: 1035–44. - PubMed
1. Dance D. Treatment and prophylaxis of melioidosis. Int J Antimicrob Agents 2014; 43: 310–8. - PMC - PubMed
1. Schweizer HP. Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. Future Microbiol 2012; 7: 1389–99. - PMC - PubMed
1. Podnecky NL, Rhodes KA, Schweizer HP.. Efflux pump-mediated drug resistance in Burkholderia. Front Microbiol 2015; 6: 305.. - PMC - PubMed
1. Chaowagul W, Suputtamongkul Y, Smith MD. et al. Oral fluoroquinolones for maintenance treatment of melioidosis. Trans R Soc Trop Med Hyg 1997; 91: 599–601. - PubMed